Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Microdosing

MDMA for Microdosing

3 papers and 0 clinical trials exploring mdma as a treatment for microdosing.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationAround 300 million people worldwide are affected by a variety of mental health conditions that microdosing may address.

Microdosing

Microdosing involves the regular consumption of sub-hallucinogenic doses of psychedelics, primarily for cognitive enhancement and emotional wellbeing. Although popularised through anecdotal reports, rigorous scientific evidence on its effects is still limited, pointing to a critical need for further research in this emerging field.

Full Microdosing profile

Academic Research

3 papers
Paywallmeta

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

This review (2023) covers in vitro, animal, and clinical studies to assess the potential risk of valvular heart disease (VHD) from microdosing psychedelic substances, focusing on LSD, psilocybin, mescaline, DMT, and MDMA due to their interaction with the serotonin 5-HT2B receptor. Findings show that all these compounds, except mescaline (due to low potency), were partial agonists at the 5-HT2B receptor. While safety margins from typical microdoses were greater than known valvulopathogens, there remains a potential risk. No studies directly evaluated VHD risk for the four psychedelics, but some evidence suggests chronic ingestion of full doses of MDMA might be linked to VHD.

Published
August 12, 2023
Journal
Journal of Psychopharmacology
Authors
Tagen, M., Mantuani, D., Van Heerden, L., Holstein, A., Klumpers, L. E., Knowles, R.
Open Accessmeta

Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines

A PRISMA-guided systematic review of ergolamines, simple tryptamines and phenylethylamines (33 studies from 3,032 records) finds that classic psychedelics are active at very low doses, non‑addictive and generally only harmful at extremely high doses, with no established lethal dose for LSD or psilocybin. MDMA appears to carry the greatest apparent toxicity—likely confounded by recreational misuse—and the authors emphasise that risk is strongly modulated by set and setting.

Published
February 3, 2023
Journal
Toxics
Authors
Henríquez-Hernández, L. A., Rojas-Hernández, J., Quintana-Hernández, D. J., Borkel, L. F.
Paywallindividual

Micro-dosing psychedelics as a plausible adjunct to psychosexual and couple’s therapy: a qualitative insight

This interview study (n=4 couples) explored the MDMA micro-dosing sexual experiences of four partnered men and women. Thematic analysis identified three key narratives: increased sexual self-efficacy; sexual exploration; and heightened relationship satisfaction. The use of microdosing MDMA had a positive effect on sexual and physical well-being by reducing stress and performance-related anxiety. Whilst higher doses of MDMA hindered sexual functioning this did not negatively impact the emotional and sensory experiences.

Published
February 28, 2022
Journal
Sexual and Relationship Therapy
Authors
Jacobs, L., Banbury, S., Lusher, J.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Microdosing yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Microdosing trials Full MDMA profile Full Microdosing profile